Semiannual Report — FY2026 H1
What BrightPath Biotherapeutics Co.,Ltd. reported for the period from 2026-04-01 to 2027-03-31.
Filed 2026-11-13View the original on EDINET
How much it says
52Typical
What moved here
9named for the first time
Its own wording
23terms
Which filing this is
38/ 38newest
No officer data yetThis company's filings have not been read for officers yet. Nothing is missing from the filings — the roster simply has not been extracted.
The gist
During the interim accounting period, the Company advanced research and development aimed at creating novel cancer immunotherapies. BP2202's IND was accepted by the FDA at the end of July 2026, enabling the start of a Phase I clinical trial in the United States. In addition, a resolution was passed in October 2026 to issue stock acquisition rights through a third-party allotment, and the resulting financing and share issuance through partial exercise were disclosed as subsequent events.
Komori's summary of this document, not the document's own words.52Typical
How much this filing saysA weighted roll-up of 9 rubric dimensions, each scored from a fixed set of questions asked against this filing — built only from the 33 this document could answer. It measures how specific the disclosure is, not whether the company is doing well. Derived from the data, not editorial.
73
Detailed
61
Detailed
11
Almost nothing
50
Typical
68
Detailed
35
Thin
53
Typical
55
Typical
60
Detailed
R&D spend12億円Money spent making new things.
Cash left over-9億円Cash from the business, less what went into equipment.
Spent on equipmentNot disclosedThis document does not carry the figure.
EmployeesNot disclosedThis document does not carry the figure.
How to read this page
This is not the documentIt is Komori's reading of the filing submitted to EDINET. The original is linked above.
The score is not a verdictIt measures how specific the disclosure is. It says nothing about results or where the share price goes.
When it updatesContent lands once the filing has been read through. Right after submission, the summary can still be empty.